Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

Figure 2

Combined effect of IL-18 rs5744247 and rs1946518 and CYP3A5 rs776746 polymorphisms on tacrolimus concentration/dose (C/D) ratios in lung transplant patients at week 1 (a), week 2 (b), week 3 (c), and week 4 (d) following transplantation. The lung transplant recipients were divided into 4 groups according to the number of IL-18 alleles associated with fast tacrolimus metabolism and CYP3A5 genotype: Group 1 (CYP3A5 expresser and the number of alleles greater than or equal to 3); Group 2 (CYP3A5 expressers and the number of alleles less than or equal to 2); Group 3 (CYP3A5 nonexpresser and the number of alleles greater than or equal to 3); Group 4 (CYP3A5 nonexpressers and the number of alleles less than or equal to 2). Among the patients with CYP3A5 expression genotype, the impact of IL-18 polymorphisms on tacrolimus C/D ratios was significant.

(a)

(b)

(c)

(d)